Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Prices €5.25B Notes Offering

NEW YORK – Thermo Fisher Scientific said on Wednesday that it has priced an offering of €5.25 billion ($6.06 billion) aggregate principal amount of four types of euro-denominated notes.

The company is offering €1.75 billion aggregate principal amount of its 0.8 percent senior notes due 2030 at the issue price of 99.81 percent of their principal amount; €1.5 billion aggregate principal amount of its 1.125 percent senior notes due 2033 at the issue price of 99.732 percent of their principal amount; €1.25 billion aggregate principal amount of its 1.625 percent senior notes due 2041 at the issue price of 98.171 percent of their principal amount; and €750 million aggregate principal amount of its 2 percent senior notes due 2051 at the issue price of 99.331 percent of their principal amount.

The notes will be issued by the firm's indirect, wholly owned finance subsidiary, Thermo Fisher Scientific BV, and will be fully and unconditionally guaranteed by Thermo Fisher. They will pay interest on an annual basis, the company said.

The offering is expected to close on or about October 18. Barclays Bank, Morgan Stanley Europe, BofA Securities Europe, Citigroup Global Markets Europe, and Mizuho Securities Europe are acting as joint bookrunning managers.

Thermo Fisher said it intends to use the net proceeds to pay a portion of the cash consideration for its pending acquisition of PPD. The company agreed in April to pay $17.4 billion for the clinical research services provider, plus the assumption of approximately $3.5 billion of net debt.

In August, Thermo Fisher priced an offering of $3.1 billion aggregate principal amount of three types of senior notes, and also said it would use the proceeds from that sale to pay for part of the cash consideration of the PPD acquisition.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.